New data demonstrates potential utility of next-generation sequencing based MRD testing as a surrogate endpoint for multiple myeloma clinical trials

Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and collaborators… Source link